Home > Search Results


A recommendation to extend antiviral treatment to patients who did not respond to, or who relapsed from, a previous course of peginterferon alfa and ribavirin combination therapy may increase the number of eligible patients in some areas, with resultant budget implications for primary care trusts and increased use of hepatology services.

Recent Activity

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...